Rehabilitation Research News:
March 19, 2021

NICHD Notices and Funding Opportunities

• Request for Information (RFI): Invitation to Comment on the Draft NIH INvestigation of Co-occuring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Down Syndrome Research Plan
  • (NOT-HD-21-014)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development 
  • Office of the Director, NIH 
  • Application Receipt Date: May 5, 2021 
     
• BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)
  • (RFA-MH-21-130)
  • Multiple Institutes 
  • Application Receipt Date: October 7, 2021 
     
• BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) 
  • (RFA-MH-21-135)
  • Multiple Institutes 
  • Application Receipt Dates: October 15, 2021; June 10, 2022; October 14, 2022; June 9, 2023; October 13, 2023; June 7, 2024. All applications are due by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 
     
• Firearm Injury and Mortality Prevention Research (R21/R33 Clinical Trial Optional)
  • (PAR-21-191)
  • Multiple Institutes
  • Application Receipt Date: April 30, 2021. All applications are due by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
     
• Firearm Injury and Mortality Prevention Research (R01Clinical Trial Optional)
  • (PAR-21-192)
  • Multiple Institutes
  • Application Receipt Date: April 30, 2021. All applications are due by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
     
• Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
  • (PAR-21-163)
  • Multiple Institutes
  • Application Receipt Dates: August 10, 2021; February 9, 2022; August 9, 2022; February 9, 2023; August 9, 2023; February 9, 2024. All applications are due by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

NIH Notices and Funding Opportunities

• Upcoming Changes to the Biographical Sketch and Other Support Format Page for Due Dates on or after May 25, 2021
  • (NOT-OD-21-073)
  • National Institutes of Health
     
• Announcement of Childcare Costs for Ruth L. Kirschstein National Service Award (NRSA) Individual Fellows
  • (NOT-OD-21-069)
  • National Institutes of Health
     
• Request for Information (RFI): Inviting Comments and Suggestions to Advance and Strengthen Racial Equity, Diversity, and Inclusion in the Biomedical Research Workforce and Advance Health Disparities and Health Equity Research
  • (NOT-OD-21-066)
  • Office of the Director, National Institutes of Health 
     
• Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42 - Clinical Trial Optional) 
  • (RFA-MD-21-005)
  • National Institute on Minority Health and Health Disparities
  • Application Receipt Date: May 3, 2021. No late applications will be accepted for this Funding Opportunity Announcement. All applications are due by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
     
• Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)
  • (RFA-MD-21-006)
  • National Institute on Minority Health and Health Disparities 
  • Application Receipt Date(s): May 3, 2021. No late applications will be accepted for this Funding Opportunity Announcement. All applications are due by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
     
• Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
  • (PAR-21-122)
  • National Institute of Neurological Disorders and Stroke 
  • Application Receipt Dates: June 17, 2021; October 19, 2021; February 22, 2022; June 21, 2022; October 18, 2022; February 21, 2023; June 20, 2023; October 20, 2023; February 20, 2024. All applications are due by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
     
• Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
  • (PAR-21-123)
  • National Institute of Neurological Disorders and Stroke 
  • Application Receipt Dates: June 17, 2021; October 19, 2021; February 22, 2022; June 21, 2022; October 18, 2022; February 21, 2023; June 20, 2023; October 20, 2023; February 20, 2024. All applications are due by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
     
• Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R633 Clinical Trial Not Allowed)
  • (PAR-21-124)
  • National Institute of Neurological Disorders and Stroke 
  • National Center for Complementary and Integrative Health 
  • Application Receipt Dates: June 17, 2021; October 19, 2021; February 22, 2022; June 21, 2022; October 18, 2022; February 21, 2023; June 20, 2023; October 20, 2023; February 20, 2024. All applications are due by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

HHS Notices and Funding Opportunities

The National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR), part of the HHS Administration for Community Living, is publishing its funding opportunities for this fiscal year to Grants.gov. All open opportunities are listed below. 

• Disability and Rehabilitation Research Projects (DRRP) Program: National Research Center for Parents with Disabilities Synopsis 1 
  • Department of Health and Human Services
  • Administration for Community Living 
     
• Disability and Rehabilitation Research Projects (DRRP) Program: Reducing Social Isolation and Loneliness among People with Disabilities Synopsis 2
  • Department of Health and Human Services 
  • Administration for Community Living 
     
• Spinal Cord Injury Model Systems Synopsis 1 
  • Department of Health and Human Services 
  • Administration for Community Living 

Other Notices 

The American Association on Health and Disability (AAHD) is very concerned about the impact of COVID-19 on persons with disabilities and has launched a cross-disability survey to look at vaccine hesitancy and access challenges people with disabilities are encountering. The objective of the COVID-19 and Vaccine Survey for Adults with Disabilities is to better understand why adults with disabilities have taken or will take the vaccine, are not sure about taking the vaccine, or have decided not to take the vaccine. This information will be shared with the disability community, health and public health professionals, policymakers, and researchers.

The survey  will be open from March 12, 2021, to March 26, 2021.

The average completion time for the survey is less than 8 minutes. The survey asks a series of disability-specific and general questions about vaccine decisions. Alternate formats, such as large print, Braille, or electronic versions of the survey, are available upon request at jditsch@aahd.us . For more information about the survey, contact Charles E. Drum, Ph.D., M.P.A., J.D., at cdrum@aahd.us  or 301-545-6140, extension 5. Please note: This survey is not sponsored by NIH.